Metformin for cardiovascular disease: Promise still unproven

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 2, 2014, Pages 94-95

  Lexis, Chris P H ^a   Van der Horst, Iwan C C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ARTERIAL WALL THICKNESS; CORONARY DISEASE; FEMALE; HUMAN; INTIMA; MALE; METABOLIC SYNDROME X; PATHOLOGY;

CAROTID INTIMA-MEDIA THICKNESS; CORONARY DISEASE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; TUNICA INTIMA;

EID: 84894901204     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70171-2     Document Type: Note

References (10)

1. Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabet & Endocrinol 2013, published online Nov 7. http://dx.doi.org/10.1016/S2213-8587(13)70152-9.
2. Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008, 35:895-903.
3. Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetalogia 2004, 47:1906-1913.
4. Lundby Christensen L, Almdal T, Boesgaard T, et al. Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. Diabetes Obes Metab 2009, 11:315-322. CIMT Trial Group.
5. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007, 153:445.e1-445.e6.
6. Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 2011, 301:H459-H468.
7. Bailey CJ Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008, 22:215-224.
8. Cittadini A, Napoli R, Monti MG, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012, 61:944-953.
9. Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patient undergoing percutaneous intervention. Am J Cardiol 2004, 93:1347-1350.
10. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010, 170:1892-1899.